integra lifesciences holdings corp. - IART

IART

Close Chg Chg %
16.26 -0.19 -1.17%

Open Market

16.07

-0.19 (1.17%)

Volume: 126.76K

Last Updated:

Sep 9, 2026, 12:32 PM EDT

Company Overview: integra lifesciences holdings corp. - IART

IART Key Data

Open

$16.10

Day Range

15.99 - 16.46

52 Week Range

8.70 - 20.49

Market Cap

$1.30B

Shares Outstanding

77.77M

Public Float

66.53M

Beta

1.21

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.09

Yield

0.00%

Dividend

$6.37

EX-DIVIDEND DATE

Jul 2, 2015

SHORT INTEREST

N/A

AVERAGE VOLUME

599.31K

 

IART Performance

1 Week
 
-2.75%
 
1 Month
 
-5.74%
 
3 Months
 
-8.50%
 
1 Year
 
7.97%
 
5 Years
 
-76.85%
 

IART Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About integra lifesciences holdings corp. - IART

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

IART At a Glance

Integra LifeSciences Holdings Corp.
1100 Campus Road
Princeton, New Jersey 08540
Phone 1-609-275-0500 Revenue 1.64B
Industry Medical Specialties Net Income -516,474,000.00
Sector Health Technology 2025 Sales Growth 1.535%
Fiscal Year-end 12 / 2026 Employees 4,427
View SEC Filings

IART Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.582
Price to Book Ratio 0.927
Price to Cash Flow Ratio 18.90
Enterprise Value to EBITDA 8.147
Enterprise Value to Sales 1.664
Total Debt to Enterprise Value 0.747

IART Efficiency

Revenue/Employee 369,379.941
Income Per Employee -116,664.558
Receivables Turnover 5.724
Total Asset Turnover 0.428

IART Liquidity

Current Ratio 2.543
Quick Ratio 1.462
Cash Ratio 0.578

IART Profitability

Gross Margin 52.705
Operating Margin 11.146
Pretax Margin -34.46
Net Margin -31.584
Return on Assets -13.521
Return on Equity -39.902
Return on Total Capital -16.787
Return on Invested Capital -17.674

IART Capital Structure

Total Debt to Total Equity 194.85
Total Debt to Total Capital 66.084
Total Debt to Total Assets 56.446
Long-Term Debt to Equity 181.378
Long-Term Debt to Total Capital 61.516
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Integra Lifesciences Holdings Corp. - IART

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.56B 1.54B 1.61B 1.64B
Sales Growth
+0.99% -1.03% +4.47% +1.53%
Cost of Goods Sold (COGS) incl D&A
629.61M 647.37M 711.77M 773.39M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
118.30M 123.51M 140.50M 151.83M
Depreciation
40.10M 40.90M 42.40M 44.80M
Amortization of Intangibles
78.20M 82.61M 98.10M 107.03M
COGS Growth
-4.00% +2.82% +9.95% +8.66%
Gross Income
928.05M 894.21M 898.75M 861.86M
Gross Income Growth
+4.67% -3.65% +0.51% -4.11%
Gross Profit Margin
+59.58% +58.01% +55.80% +52.71%
2022 2023 2024 2025 5-year trend
SG&A Expense
655.25M 633.54M 715.99M 679.60M
Research & Development
41.42M 41.94M 54.43M 34.81M
Other SG&A
613.83M 591.59M 661.56M 644.79M
SGA Growth
+7.23% -3.31% +13.01% -5.08%
Other Operating Expense
- - - 40.03M
-
Unusual Expense
9.57M 108.68M 153.56M 678.87M
EBIT after Unusual Expense
263.24M 111.95M 29.20M (496.61M)
Non Operating Income/Expense
(7.11M) 38.55M 40.65M 31.98M
Non-Operating Interest Income
5.13M 9.36M 9.92M 5.99M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
42.23M 69.43M 88.09M 98.87M
Interest Expense Growth
+50.92% +64.40% +26.87% +12.24%
Gross Interest Expense
43.63M 71.83M 92.59M 103.87M
Interest Capitalized
1.40M 2.40M 4.50M 5.00M
Pretax Income
213.89M 81.07M (18.24M) (563.50M)
Pretax Income Growth
-0.36% -62.10% -122.50% -2,989.88%
Pretax Margin
+13.73% +5.26% -1.13% -34.46%
Income Tax
33.34M 13.33M (11.29M) (47.03M)
Income Tax - Current - Domestic
28.04M 13.82M 1.07M 8.42M
Income Tax - Current - Foreign
9.89M 11.39M 8.37M 10.82M
Income Tax - Deferred - Domestic
(13.91M) (18.97M) (31.24M) (43.62M)
Income Tax - Deferred - Foreign
9.32M 7.08M 10.51M (22.65M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
180.55M 67.74M (6.94M) (516.47M)
Minority Interest Expense
- - - -
-
Net Income
180.55M 67.74M (6.94M) (516.47M)
Net Income Growth
+6.79% -62.48% -110.25% -7,337.70%
Net Margin Growth
+11.59% +4.39% -0.43% -31.58%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
180.55M 67.74M (6.94M) (516.47M)
Preferred Dividends
- - - -
-
Net Income Available to Common
180.55M 67.74M (6.94M) (516.47M)
EPS (Basic)
2.1754 0.8458 -0.0902 -6.7362
EPS (Basic) Growth
+8.98% -61.12% -110.66% -7,368.07%
Basic Shares Outstanding
83.00M 80.09M 77.01M 76.67M
EPS (Diluted)
2.1619 0.8432 -0.0902 -6.7362
EPS (Diluted) Growth
+9.31% -61.00% -110.70% -7,368.07%
Diluted Shares Outstanding
83.52M 80.34M 77.01M 76.67M
EBITDA
391.10M 344.15M 323.26M 334.09M
EBITDA Growth
-2.03% -12.01% -6.07% +3.35%
EBITDA Margin
+25.11% +22.32% +20.07% +20.43%

Snapshot

Average Recommendation HOLD Average Target Price 18.556
Number of Ratings 12 Current Quarters Estimate 0.564
FY Report Date 09 / 2026 Current Year's Estimate 2.457
Last Quarter’s Earnings 0.56 Median PE on CY Estimate N/A
Year Ago Earnings 2.23 Next Fiscal Year Estimate 2.609
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 12 12
Mean Estimate 0.56 0.80 2.46 2.61
High Estimates 0.59 0.89 2.50 2.73
Low Estimate 0.53 0.74 2.41 2.50
Coefficient of Variance 2.93 5.13 0.96 2.95

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 7 7 5
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Integra Lifesciences Holdings Corp. in the News